Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection

Benjamin Wizel, Nisha Garg, Rick L. Tarleton

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

DNA vaccination was evaluated with the experimental murine model of Trypanosoma cruzi infection as a means to induce antiparasite protective immunity, and the trypomastigote surface antigen 1 (TSA-1), a target of anti- T. cruzi antibody and major histocompatibility complex (MHC) class I- restricted CD8+ cytotoxic T-lymphocyte (CTL) responses, was used as the model antigen. Following the intramuscular immunization of H-2(b) and H-2(d) mice with a plasmid DNA encoding an N-terminally truncated TSA-1 lacking or containing the C-terminal nonapeptide tandem repeats, the antibody level, CTL response, and protection against challenge with T. cruzi were assessed. In H- 2(b) mice, antiparasite antibodies were induced only by immunization with the DNA construct encoding TSA-1 containing the C-terminal repeats. However, both DNA constructs were efficient in eliciting long-lasting CTL responses against the protective H-2K(b)-restricted TSA-1;515-522) epitope. In Hs(d) mice, inoculation with either of the two TSA-1-expressing vectors effectively generated antiparasite antibodies and primed CTLs that lysed T. cruzi- infected cells in an antigen-specific, MHC class I-restricted, and CD8+-T- cell-dependent manner. When TSA-1 DNA-vaccinated animals were challenged with T. cruzi, 14 of 22 (64%) H-2(b) and 16 of 18 (89%) H-2(d) mice survived the infection. The ability to induce significant murine anti-T. cruzi protective immunity by immunization with plasmid DNA expressing TSA-1 provides the basis for the application of this technology in the design of optimal DNA multicomponent anti-T. cruzi vaccines which may ultimately be used for the prevention or treatment of Chagas' disease.

Original languageEnglish (US)
Pages (from-to)5073-5081
Number of pages9
JournalInfection and Immunity
Volume66
Issue number11
StatePublished - 1998
Externally publishedYes

Fingerprint

Trypanosoma cruzi
Surface Antigens
Vaccination
Plasmids
DNA
Infection
Cytotoxic T-Lymphocytes
Immunization
Antibodies
Major Histocompatibility Complex
Immunity
Antigens
Tandem Repeat Sequences
Chagas Disease
Terminal Repeat Sequences
Epitopes
Theoretical Models
Vaccines
Technology
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology

Cite this

Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. / Wizel, Benjamin; Garg, Nisha; Tarleton, Rick L.

In: Infection and Immunity, Vol. 66, No. 11, 1998, p. 5073-5081.

Research output: Contribution to journalArticle

@article{21528e670f2744feba9076488727780a,
title = "Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection",
abstract = "DNA vaccination was evaluated with the experimental murine model of Trypanosoma cruzi infection as a means to induce antiparasite protective immunity, and the trypomastigote surface antigen 1 (TSA-1), a target of anti- T. cruzi antibody and major histocompatibility complex (MHC) class I- restricted CD8+ cytotoxic T-lymphocyte (CTL) responses, was used as the model antigen. Following the intramuscular immunization of H-2(b) and H-2(d) mice with a plasmid DNA encoding an N-terminally truncated TSA-1 lacking or containing the C-terminal nonapeptide tandem repeats, the antibody level, CTL response, and protection against challenge with T. cruzi were assessed. In H- 2(b) mice, antiparasite antibodies were induced only by immunization with the DNA construct encoding TSA-1 containing the C-terminal repeats. However, both DNA constructs were efficient in eliciting long-lasting CTL responses against the protective H-2K(b)-restricted TSA-1;515-522) epitope. In Hs(d) mice, inoculation with either of the two TSA-1-expressing vectors effectively generated antiparasite antibodies and primed CTLs that lysed T. cruzi- infected cells in an antigen-specific, MHC class I-restricted, and CD8+-T- cell-dependent manner. When TSA-1 DNA-vaccinated animals were challenged with T. cruzi, 14 of 22 (64{\%}) H-2(b) and 16 of 18 (89{\%}) H-2(d) mice survived the infection. The ability to induce significant murine anti-T. cruzi protective immunity by immunization with plasmid DNA expressing TSA-1 provides the basis for the application of this technology in the design of optimal DNA multicomponent anti-T. cruzi vaccines which may ultimately be used for the prevention or treatment of Chagas' disease.",
author = "Benjamin Wizel and Nisha Garg and Tarleton, {Rick L.}",
year = "1998",
language = "English (US)",
volume = "66",
pages = "5073--5081",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection

AU - Wizel, Benjamin

AU - Garg, Nisha

AU - Tarleton, Rick L.

PY - 1998

Y1 - 1998

N2 - DNA vaccination was evaluated with the experimental murine model of Trypanosoma cruzi infection as a means to induce antiparasite protective immunity, and the trypomastigote surface antigen 1 (TSA-1), a target of anti- T. cruzi antibody and major histocompatibility complex (MHC) class I- restricted CD8+ cytotoxic T-lymphocyte (CTL) responses, was used as the model antigen. Following the intramuscular immunization of H-2(b) and H-2(d) mice with a plasmid DNA encoding an N-terminally truncated TSA-1 lacking or containing the C-terminal nonapeptide tandem repeats, the antibody level, CTL response, and protection against challenge with T. cruzi were assessed. In H- 2(b) mice, antiparasite antibodies were induced only by immunization with the DNA construct encoding TSA-1 containing the C-terminal repeats. However, both DNA constructs were efficient in eliciting long-lasting CTL responses against the protective H-2K(b)-restricted TSA-1;515-522) epitope. In Hs(d) mice, inoculation with either of the two TSA-1-expressing vectors effectively generated antiparasite antibodies and primed CTLs that lysed T. cruzi- infected cells in an antigen-specific, MHC class I-restricted, and CD8+-T- cell-dependent manner. When TSA-1 DNA-vaccinated animals were challenged with T. cruzi, 14 of 22 (64%) H-2(b) and 16 of 18 (89%) H-2(d) mice survived the infection. The ability to induce significant murine anti-T. cruzi protective immunity by immunization with plasmid DNA expressing TSA-1 provides the basis for the application of this technology in the design of optimal DNA multicomponent anti-T. cruzi vaccines which may ultimately be used for the prevention or treatment of Chagas' disease.

AB - DNA vaccination was evaluated with the experimental murine model of Trypanosoma cruzi infection as a means to induce antiparasite protective immunity, and the trypomastigote surface antigen 1 (TSA-1), a target of anti- T. cruzi antibody and major histocompatibility complex (MHC) class I- restricted CD8+ cytotoxic T-lymphocyte (CTL) responses, was used as the model antigen. Following the intramuscular immunization of H-2(b) and H-2(d) mice with a plasmid DNA encoding an N-terminally truncated TSA-1 lacking or containing the C-terminal nonapeptide tandem repeats, the antibody level, CTL response, and protection against challenge with T. cruzi were assessed. In H- 2(b) mice, antiparasite antibodies were induced only by immunization with the DNA construct encoding TSA-1 containing the C-terminal repeats. However, both DNA constructs were efficient in eliciting long-lasting CTL responses against the protective H-2K(b)-restricted TSA-1;515-522) epitope. In Hs(d) mice, inoculation with either of the two TSA-1-expressing vectors effectively generated antiparasite antibodies and primed CTLs that lysed T. cruzi- infected cells in an antigen-specific, MHC class I-restricted, and CD8+-T- cell-dependent manner. When TSA-1 DNA-vaccinated animals were challenged with T. cruzi, 14 of 22 (64%) H-2(b) and 16 of 18 (89%) H-2(d) mice survived the infection. The ability to induce significant murine anti-T. cruzi protective immunity by immunization with plasmid DNA expressing TSA-1 provides the basis for the application of this technology in the design of optimal DNA multicomponent anti-T. cruzi vaccines which may ultimately be used for the prevention or treatment of Chagas' disease.

UR - http://www.scopus.com/inward/record.url?scp=0032425402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032425402&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 5073

EP - 5081

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 11

ER -